S2k-Leitlinie Neuroendokrine Tumore

Zusammenfassung Diese erstmals erstellte Leitlinie soll als praktische Hilfe für die Diagnostik und Therapie neuroendokriner Tumore dienen. Sie soll den aktuellen Stand der Wissenschaft darstellen, das Erkennen der Erkrankung fördern und die Behandlung der Patienten verbessern. Die Leitlinie wurde unter Federführung der DGVS und mit Beteiligung benachbarter Fachgebiete erstellt.

• Publication year

  2018

• Venue

  Zeitschrift für Gastroenterologie - German Journal of Gastroenterology

• Publication date

  2018-06-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1055/a-0604-2924PMID 29890561
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study

  2018cited by this paper
• Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis

  2018cited by this paper
• The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors

  2017cited by this paper
• Diagnosing and Managing Carcinoid Heart Disease in Patients With Neuroendocrine Tumors: An Expert Statement.

  2017cited by this paper
• Mesenteric Fibrosis in Midgut Neuroendocrine Tumors: Functionality and Radiological Features

  2017cited by this paper
• Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary

  2017cited by this paper
• Critical Questions Regarding Gadolinium Deposition in the Brain and Body After Injections of the Gadolinium-Based Contrast Agents, Safety, and Clinical Recommendations in Consideration of the EMA's Pharmacovigilance and Risk Assessment Committee Recommendation for Suspension of the Marketing Authori

  2017cited by this paper
• Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518.

  2017cited by this paper
• Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors

  2017cited by this paper
• Clinical, pathological, and demographic factors associated with development of recurrences after surgical resection in elderly patients with neuroendocrine tumors

  2017cited by this paper
• Recurrence 30 Years after Surgical Resection of a Localized Rectal Neuroendocrine Tumor

  2017cited by this paper
• Effect of lanreotide depot (LAN) on 5-hydroxyindoleacetic acid (5HIAA) and chromogranin A (CgA) in gastroenteropancreatic neuroendocrine (GEP NET) tumors: Correlation with tumor response and progression-free survival (PFS) from the phase III CLARINET study.

  2017cited by this paper
• Everolimus in Pancreatic Neuroendocrine Carcinomas G3

  2017cited by this paper
• ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers

  2017cited by this paper
• ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology - Diagnosis and Prognostic Stratification

  2017cited by this paper
• ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging

  2017cited by this paper
• ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours

  2017cited by this paper
• A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

  2017cited by this paper
• Glucagonoma-Associated Rash.

  2017cited by this paper
• Bone Metastases in Patients with Neuroendocrine Neoplasm: Frequency and Clinical, Therapeutic, and Prognostic Relevance

  2017cited by this paper
• Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors

  2017cited by this paper
• Chromogranin A as a valid marker in oncology: Clinical application or false hopes?

  2017cited by this paper
• ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents

  2017cited by this paper
• Carcinoid syndrome from a carcinoid tumor of the pancreas without liver metastases: A case report and literature review.

  2017cited by this paper
• ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues

  2017cited by this paper
• Radioembolization of Hepatic Malignancies: Background, Quality Improvement Guidelines, and Future Directions.

  2017cited by this paper
• Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.

  2017cited by this paper
• Radioembolization-induced liver disease: a systematic review

  2017cited by this paper
• Localization of Insulinoma Using 68Ga-DOTATATE PET/CT Scan

  2017cited by this paper
• Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers

  2017cited by this paper
• Single‐institution experience of radioembolization with yttrium‐90 microspheres for unresectable metastatic neuroendocrine liver tumors

  2017cited by this paper
• ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation

  2017cited by this paper
• Initial Experience with CT-Guided High-Dose-Rate Brachytherapy in the Multimodality Treatment of Neuroendocrine Tumor Liver Metastases.

  2017cited by this paper
• The prognostic influence of the proliferative discordance in metastatic pancreatic neuroendocrine carcinoma revealed by peptide receptor radionuclide therapy

  2017cited by this paper
• Percutaneous Ablation of Hepatic Tumors Using Irreversible Electroporation: A Prospective Safety and Midterm Efficacy Study in 34 Patients.

  2016cited by this paper
• Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours.

  2016cited by this paper
• Management of gastric and duodenal neuroendocrine tumors.

  2016cited by this paper
• Sporadic Gastric Well-Differentiated Neuroendocrine Tumors Have a Higher Ki-67 Proliferative Index

  2016cited by this paper
• Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma

  2016cited by this paper
• Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.

  2016cited by this paper
• (68)Ga-DOTATOC PET and gene expression profile in patients with neuroendocrine carcinomas: strong correlation between PET tracer uptake and gene expression of somatostatin receptor subtype 2.

  2016cited by this paper
• Resection of rectal carcinoids with the newly introduced endoscopic full-thickness resection device

  2016cited by this paper
• Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement

  2016cited by this paper
• Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.

  2016cited by this paper
• Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors

  2016cited by this paper
• Role of 68Ga somatostatin receptor PET/CT in the detection of endogenous hyperinsulinaemic focus: an explorative study

  2016cited by this paper
• Malignant-functioning neuroendocrine tumors of the pancreas: A survival analysis.

  2016cited by this paper
• Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors.

  2016cited by this paper
• Neuroendokrine Tumoren des Rektums: endoskopische Therapie

  2016cited by this paper
• Embolotherapy for Neuroendocrine Tumor Liver Metastases: Prognostic Factors for Hepatic Progression-Free Survival and Overall Survival

  2016cited by this paper
• ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site

  2016cited by this paper
• Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.

  2016cited by this paper
• Evaluation of Magnetic Resonance (MR) Biomarkers for Assessment of Response With Response Evaluation Criteria in Solid Tumors: Comparison of the Measurements of Neuroendocrine Tumor Liver Metastases (NETLM) With Various MR Sequences and at Multiple Phases of Contrast Administration

  2016cited by this paper
• Glucagon-Like Peptide-1 Receptor PET/CT with 68Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study

  2016cited by this paper
• Oxaliplatin–Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials

  2016cited by this paper
• Evaluation of the Added Value of Diffusion-Weighted Imaging to Conventional Magnetic Resonance Imaging in Pancreatic Neuroendocrine Tumors and Comparison With 68Ga-DOTANOC Positron Emission Tomography/Computed Tomography

  2016cited by this paper
• Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors

  2016cited by this paper
• Neuroendocrine Tumors of the Urinary Bladder According to the 2016 World Health Organization Classification: Molecular and Clinical Characteristics

  2016cited by this paper
• ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors

  2016cited by this paper
• Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?

  2016cited by this paper
• Active Surveillance versus Surgery of Nonfunctioning Pancreatic Neuroendocrine Neoplasms ≤2 cm in MEN1 Patients

  2016cited by this paper
• Maximizing Information From Routine Staging Computed Tomography in Functional Neuroendocrine Neoplasms: Are There Findings Indicating the Presence of Carcinoid Heart Disease?

  2016cited by this paper
• ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum

  2016cited by this paper
• Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres.

  2016cited by this paper
• ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms

  2016cited by this paper
• Short- and long-term outcomes of endoscopic resection of rectal neuroendocrine tumours: analyses according to the WHO 2010 classification

  2016cited by this paper
• Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours.

  2016cited by this paper
• Cap-assisted EMR for rectal neuroendocrine tumors: comparisons with conventional EMR and endoscopic submucosal dissection (with videos).

  2016cited by this paper
• Endoscopic submucosal resection with a ligation device for the treatment of duodenal neuroendocrine tumors

  2016cited by this paper
• Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up.

  2016cited by this paper
• ENETS Consensus Guidelines for Neuroendocrine Neoplasms of the Appendix (Excluding Goblet Cell Carcinomas)

  2016cited by this paper
• Four Neuroendocrine Tumor Types and Neuroendocrine Carcinoma of the Duodenum: Analysis of 203 Cases

  2016cited by this paper
• ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas

  2016cited by this paper
• Ki-67 index and response to chemotherapy in patients with neuroendocrine tumours.

  2016cited by this paper
• Syndromic versus non-syndromic sporadic gastrin-producing neuroendocrine tumors of the duodenum: comparison of pathological features and biological behavior

  2016cited by this paper
• Minimally Invasive Versus Open Pancreatic Surgery in Patients with Multiple Endocrine Neoplasia Type 1

  2016cited by this paper
• Low dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumors

  2016cited by this paper
• Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study

  2016cited by this paper
• Targeted Therapies Provide Treatment Options for Poorly Differentiated Pancreatic Neuroendocrine Carcinomas

  2016cited by this paper
• Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival

  2016cited by this paper
• ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms

  2016cited by this paper
• Erratum to: Surgical therapy of neuroendocrine neoplasm with hepatic metastasis: patient selection and prognosis

  2015cited by this paper
• Prognostic Significance of Lymph Node Metastases in Small Intestinal Neuroendocrine Tumors

  2015cited by this paper
• Radiation-Induced Liver Damage: Correlation of Histopathology with Hepatobiliary Magnetic Resonance Imaging, a Feasibility Study

  2015cited by this paper
• Distal Pancreatic Resection for Neuroendocrine Tumors: Is Laparoscopic Really Better than Open?

  2015cited by this paper
• Microwave Ablation Compared to Radiofrequency Ablation for Hepatic Lesions: A Meta-Analysis.

  2015cited by this paper
• Contribution of 111In-pentetreotide SPECT/CT imaging to conventional somatostatin receptor scintigraphy in the detection of neuroendocrine tumours

  2015cited by this paper
• Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate

  2015cited by this paper
• Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects

  2015cited by this paper
• Interventional radiology: role in the treatment of liver metastases from GEP-NETs

  2015cited by this paper
• CUP Syndrome in Neuroendocrine Neoplasia: Analysis of Risk Factors and Impact of Surgical Intervention

  2015cited by this paper
• Differential diagnosis of pancreatic cancer from other solid tumours arising from the periampullary area on MDCT

  2015cited by this paper
• Appendiceal goblet cell carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

  2015cited by this paper
• Is There an Additional Value of Using Somatostatin Receptor Subtype 2a Immunohistochemistry Compared to Somatostatin Receptor Scintigraphy Uptake in Predicting Gastroenteropancreatic Neuroendocrine Tumor Response?

  2015cited by this paper
• Role of Locoregional and Systemic Approaches for the Treatment of Patients with Metastatic Neuroendocrine Tumors

  2015cited by this paper
• Bone metastases and skeletal-related events from neuroendocrine tumors

  2015cited by this paper
• Parenchyma-Sparing, Limited Pancreatic Head Resection for Benign Tumors and Low-Risk Periampullary Cancer—a Systematic Review

  2015cited by this paper
• Risk of Liver Abscess Formation in Patients with Prior Biliary Intervention Following Yttrium-90 Radioembolization

  2015cited by this paper
• Goblet cell appendiceal tumors--management dilemmas and long-term outcomes.

  2015cited by this paper
• Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma.

  2015cited by this paper

• Neuroendokrine Tumoren des Gastrointestinaltraktes

  2025cites this paper
• 60/m mit wässrigen Diarrhöen und anfallsweise auftretender Hautrötung

  2025cites this paper
• A retrospective evaluation of the use of somatostatin receptor targeting radioligand therapy in neuroendocrine tumor patients in routine clinical care in Germany

  2025cites this paper
• International, multicenter analysis of endoscopic full-thickness resection of duodenal neuroendocrine tumors.

  2025cites this paper
• Outcome of Debulking the Mesenteric Mass in Symptomatic Patients with Locally Advanced Small Intestine Neuroendocrine Tumors

  2025cites this paper
• Results of Surgical Reintervention After Suboptimal Initial Resection for Locoregional Neuroendocrine Tumors of the Small Intestine

  2025cites this paper
• Comparison of the Hematotoxicity of PRRT with Lutathera® and Locally Manufactured 177Lu-HA-DOTATATE in Patients with Neuroendocrine Tumors and the Impact of Different Application Intervals

  2025cites this paper
• Indications and outcome of surgery for small nonfunctioning pancreatic neuroendocrine neoplasms (≤2 cm).

  2025cites this paper
• Nuklearmedizinische Therapien bei neuroendokrinen Tumoren

  2025cites this paper
• Nichtkolorektale Lebermetastasen – Indikationen und therapeutisches Vorgehen

  2025cites this paper
• Subepitheliale Tumoren des oberen Gastrointestinaltrakts

  2025cites this paper
• Retrospective analysis of criteria for oncological completion surgery of neuroendocrine tumors of the appendix

  2025cites this paper
• One-day dual-tracer examination in neuroendocrine neoplasms: a real advantage of low activity LAFOV PET imaging

  2025cites this paper
• Structured reporting of neuroendocrine tumors in PET/CT using [18F]SiTATE - impact on interdisciplinary communication

  2025cites this paper
• Lokale Resektion von neuroendokrinen Tumoren des Dünndarms (SI-NEN)

  2024cites this paper
• Influence of Lymphatic, Microvascular and Perineural Invasion on Oncological Outcome in Patients with Neuroendocrine Tumors of the Small Intestine

  2024cites this paper
• Individualisiertes Vorgehen bei MEN1-assoziierten duodenopankreatischen neuroendokrinen Neoplasien

  2024cites this paper
• Peer‐to‐peer validation of Ki‐67 scoring in a pathology quality circle as a tool to assess interobserver variability: are we better than we thought?

  2024cites this paper
• [Gastroenteropancreatic neuroendocrine neoplasms-Surgery in a multimodal concept].

  2024cites this paper
• Bildgebung von neuroendokrinen Tumoren des Gastrointestinaltrakts

  2024cites this paper
• Nuklearmedizinische Ansätze in Diagnostik und Therapie neuroendokriner Neoplasien

  2024cites this paper
• Systemtherapie von neuroendokrinen Neoplasien

  2024cites this paper
• When Should Lymphadenectomy Be Performed in Non-Metastatic Pancreatic Neuroendocrine Tumors? A Population-Based Analysis of the German Clinical Cancer Registry Group

  2024cites this paper
• Multiple Endocrine Neoplasia Type 1: The Current Status of Disease Management.

  2024cites this paper
• Indikation und operative Verfahren bei MEN1-assoziierten duodenopankreatischen neuroendokrinen Neoplasien

  2023cites this paper
• Neoplasms of the Appendix.

  2023cites this paper
• Diagnostic performance of PET/CT in the detection of liver metastases in well-differentiated NETs

  2023cites this paper
• Small bowel neuroendocrine tumors: An analysis of clinical presentation, diagnostic workup and surgical approach—A single center retrospective study

  2023cites this paper
• Diagnostik von neuroendokrinen Neoplasien am Beispiel der GEP-NEN

  2023cites this paper
• Systemtherapie von neuroendokrinen Tumoren

  2023cites this paper
• Primäre und sekundäre Lebertumore – aus Sicht der Nuklearmedizin

  2023cites this paper
• Indikation und operative Verfahren bei MEN1-assoziierten duodenopankreatischen neuroendokrinen Neoplasien Indication and Surgical Procedures for MEN1-associated Duodenopancreatic Neuroendocrine Neoplasms

  2023influential citation
• Are Tumor Marker Tests Applied Appropriately in Clinical Practice? A Healthcare Claims Data Analysis

  2023cites this paper
• Liver metastases of neuroendocrine tumors: Conventional transarterial chemoembolization and thermal ablation

  2023influential citation
• Diagnostic Approaches for Neuroendocrine Neoplasms of Unknown Primary (NEN-UPs) and Their Prognostic Relevance—A Retrospective, Long-Term Single-Center Experience

  2023cites this paper
• Changes in diagnosis and operative treatment of insulinoma over two decades

  2023cites this paper
• Evaluation of MRI in the diagnostic accuracy of extrahepatic metastases in neuroendocrine tumors in comparison with the reference standard somatostatin-receptor–PET/CT

  2023influential citation
• Outcome analysis in patients with metastatic gastroenteropancreatic neuroendocrine tumors receiving peptide receptor radionuclide therapy with Lu-177-DOTATATE

  2023cites this paper
• Neuroendokrine Tumoren des Pankreas

  2023cites this paper
• Nuklearmedizinische Therapieverfahren bei NET - Aktuelles und Zukünftiges

  2023cites this paper
• Theranostics bei gut bis mäßig differenzierten GEP-NEN

  2022cites this paper
• Initial Evaluation of Therapy Response after Adjuvant Radioiodine Therapy in Patients with Early-Stage Papillary Thyroid Cancer—Does Time Matter?

  2022cites this paper
• The Glasgow Prognostic Score Predicts Survival Outcomes in Neuroendocrine Neoplasms of the Gastro–Entero–Pancreatic (GEP-NEN) System

  2022cites this paper
• Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy

  2022cites this paper
• Onkologische Theranostik in der Nuklearmedizin

  2022cites this paper
• Vessel-Sparing Lymphadenectomy Should Be Performed in Small Intestine Neuroendocrine Neoplasms

  2022cites this paper
• Kontroverse: asymptomatische kleine pankreatische neuroendokrine Neoplasien

  2022cites this paper
• Watch and Wait Strategies in NET Patients: More than Expected.

  2022cites this paper
• Interventionelle Therapie bei endokrinen und neuroendokrinen Tumoren

  2022cites this paper
• Spannungsfeld endoskopische Resektionsverfahren bei GEP-NET // Endoscopic resection for GEP-NET

  2022cites this paper
• Treatment Approaches and Outcome of Patients with Neuroendocrine Neoplasia Grade 3 in German Real-World Clinical Practice

  2022cites this paper
• New Therapy Options for Neuroendocrine Carcinoma of the Pancreas—The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo

  2022influential citation
• Enucleation Is a Feasible Procedure for Well-Differentiated pNEN—A Matched Pair Analysis

  2022cites this paper
• Ungewöhnliche Ursache einer Hyperkalzämie in der Schwangerschaft

  2022cites this paper
• Onkologische Theranostik in der Nuklearmedizin

  2022cites this paper
• Chirurgie bei neuroendokrinen Neoplasien des Pankreas: State of the Art

  2022cites this paper
• Guideline adherence and implementation of tumor board therapy recommendations for patients with gastrointestinal cancer

  2022cites this paper
• Radioembolization, Principles and indications.

  2022cites this paper
• Gastroentero-pankreatische neuroendokrine Neoplasien (GEP-NEN)

  2022cites this paper
• Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [18F]SiTATE

  2022cites this paper
• Neuroendokrine Neoplasien der Appendix

  2021cites this paper
• Risk of lymph node metastasis after endoscopic treatment for rectal NETs 10 mm or less

  2021cites this paper
• PD-L1 – inhibitors in neuroendocrine neoplasia

  2021cites this paper
• Insulinoma in pregnancy (a case presentation and systematic review of the literature)

  2021cites this paper
• Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?

  2021cites this paper
• Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot

  2021cites this paper
• Leptomeningeal Carcinomatosis: A Clinical Dilemma in Neuroendocrine Neoplasms

  2021cites this paper
• Multicenter Analysis of Treatment Outcomes for Systemic Therapy in Well Differentiated Grade 3 Neuroendocrine Tumors (NET G3)

  2021cites this paper
• Konventionelle Hemikolektomie rechts mit kompletter mesokolischer Exzision (CME)

  2021cites this paper
• Targeting HDACs in Pancreatic Neuroendocrine Tumor Models

  2021cites this paper
• Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET/CT correlates with Ki-67 in liver metastases of neuroendocrine tumours

  2021cites this paper
• Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria

  2021cites this paper
• Finding the Appropriate Therapeutic Strategy in Patients with Neuroendocrine Tumors of the Pancreas: Guideline Recommendations Meet the Clinical Reality

  2021cites this paper
• Clinical Features and Prognosis of Patients with Carcinoid Syndrome and Carcinoid Heart Disease: A Retrospective Multicentric Study of 276 Patients

  2021cites this paper
• 90Y Radioembolization in the Treatment of Neuroendocrine Neoplasms: Results of an International Multicenter Retrospective Study

  2021cites this paper
• Streptozocin/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapy

  2021cites this paper
• Endokrine und neuroendokrine Tumoren

  2021cites this paper
• Transanal endoscopic microsurgery: exploring its indications and novel applications. A narrative review

  2021cites this paper
• Systemische Therapien neuroendokriner Tumoren und Karzinome

  2021cites this paper
• Sporadischer organischer Hyperinsulinismus (Insulinom)

  2021cites this paper
• Ungewöhnliche Ursache einer Hyperkalzämie in der Schwangerschaft

  2021cites this paper
• Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): study protocol for a multicenter single-arm trial

  2021cites this paper
• Peptidradiorezeptor-Therapie (PRRT)

  2021cites this paper
• Medikamentöse Systemtherapie bei Neuroendokrinen Neoplasien des GastroEnteropankreatischen Systems

  2021cites this paper
• Seltene sporadische hormonaktive pNEN: Gastrinom, Glukagonom, VIPOM

  2021cites this paper
• 90 Y radioembolization in the treatment of neuroendocrine neoplasms: Results of an international multicenter retrospective study. 90 Y RE in neuroendocrine neoplasms

  2021cites this paper
• [Gastroenteropancreatic neuroendocrine tumors].

  2021cites this paper
• Intermittierende Wahrnehmungsstörungen unter Nahrungskarenz bei einer 46-jährigen Patientin

  2020cites this paper
• Lipidologie

  2020cites this paper
• Does the proteasome inhibitor bortezomib sensitize to DNA-damaging therapy in gastroenteropancreatic neuroendocrine neoplasms? – A preclinical assessment in vitro and in vivo

  2020cites this paper
• Endoscopic full thickness resection vs. transanal endoscopic microsurgery for local treatment of rectal neuroendocrine tumors - a retrospective analysis

  2020cites this paper
• Professional Assessment of the Impact of COVID-19 on Handling NET Patients

  2020cites this paper
• ERKRANKUNGEN DER ENDOKRINEN ORGANE UND DES STOFFWECHSELS

  2020cites this paper
• Neuroendokrine Neoplasien (NEN)

  2020cites this paper
• Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumors—Results from an Exploratory Study

  2020cites this paper
• Lokale Therapieverfahren neuroendokriner Tumoren mit dem Schwerpunkt nuklearmedizinische Optionen

  2020cites this paper
• [Gastroenteropancreatic neuroendocrine neoplasms-Heterogeneity, management and perspectives of treatment and research].

  2020cites this paper
• Neuroendokrine Neoplasien des Verdauungstrakts

  2020cites this paper
• A case report of an excellent response to interferon- α in a patient with functional metastasized neuroendocrine tumor refractory to other treatments

  2020cites this paper
• Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations Are Elevated in Patients with Neuroendocrine Malignancies

  2020cites this paper